NCT02852486 2025-03-30
EDI-PIO
University of Campinas, Brazil
Phase 2 Completed
Clinical Trials
16 trialsNCT05163106 2024-08-02
NEOLETRIB
University Hospital, Akershus
Phase 2 Completed
NCT05265988 2024-07-31
MERIDIAN
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Phase 2 Completed
NCT04243122 2024-05-29
AIRPORT-MPN
Ottawa Hospital Research Institute
Phase 2 Completed
NCT03086538 2022-06-15
Pemetrexed Plus Tarceva as Salvage Treatment in EGFR Overexpressed Metastatic Colorectal Cancer Patients Who Were Failed After Standard Chemotherapy
Samsung Medical Center
Phase 2 Completed
NCT02045017 2021-08-27
Efficacy and Safety of Pomalidomide and Dexamethasone in RRMM Patients With Renal Insufficiency
Celgene
Phase 2 Completed
NCT03448731 2020-04-08
DERMIA
Fundacion CRIS de Investigación para Vencer el Cáncer
Phase 2 Completed
NCT03159845 2020-01-07
ZENITH
Azienda Ospedaliero, Universitaria Pisana
Phase 2 Completed
NCT03405168 2018-11-16
Routine Therapy Plus Moxifloxacin in Advanced Breast Cancer
Sun Yat-sen University
Phase 2 Completed
NCT03259919 2018-10-18
pilPregMet
Norwegian University of Science and Technology
Phase 2 Completed
NCT01943864 2017-05-31
A Phase IIa Study of the MEK Inhibitor Trametinib Monotherapy in the Treatment of Biliary Tract Cancers
GlaxoSmithKline
Phase 2 Completed
NCT01563055 2015-08-10
A Phase I/II, Open-label Study of Ofatumumab Added to Chlorambucil in Previously Untreated Japanese Patients With Chronic Lymphocytic Leukemia
GlaxoSmithKline
Phase 2 Completed
NCT01808326 2015-06-22
A Phase II, Open Label, Single Arm, Multicenter Study of Chlorambucil in Japanese Previously Untreated Patients With Chronic Lymphocytic Leukemia
GlaxoSmithKline
Phase 2 Completed
NCT00086203 2015-03-25
Study of Talabostat and Rituximab in Advanced Chronic Lymphocytic Leukemia (CLL)
FDA Office of Orphan Products Development
Phase 2 Completed
NCT00080080 2007-06-08
Study of Talabostat and Docetaxel in Advanced Non-Small Cell Lung Cancer
Point Therapeutics
Phase 2 Completed
NCT00083239 2007-06-08
Study of Talabostat in Advanced Melanoma
Point Therapeutics
Phase 2 Completed